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Abstract
Introduction. Mantle cell lymphoma (MCL) comprises approximately 3% to 10% of all non-Hodgkin lymphomas. Although
there is an increased risk for secondary malignancies after treatment among non-Hodgkin lymphomas survivors, a
synchronous diagnosis of primary lung cancer arising in conjunction with lymphoma at the same site has rarely been
reported. We report an unusual case of primary lung adenocarcinoma with coexistent MCL within the same lung
lesion. Case Presentation. A 55-year-old female with newly diagnosed stage IV-B MCL was referred for workup of a
right upper lobe cavitary lesion detected during lymphoma staging. A whole-body positron-emission tomographycomputed tomography scan revealed diffuse adenopathy but also identified a cavitary right upper lobe lesion atypical
for lymphoma. Bronchoscopy was unremarkable with cytology (on lavage) negative for malignancy. At 2 months, a
computed tomography scan of the chest showed a persistent lesion. A video-assisted thoracoscopic wedge resection
was performed. Histopathological examination revealed a lepidic predominant, well-differentiated adenocarcinoma
(stage T1a) and foci of lymphoid infiltrate within and adjacent to the adenocarcinoma consistent with lung involvement
by MCL. Discussion. Synchronous presentation of primary lung adenocarcinoma and lymphoma at a single site is
exceedingly rare. Nonresolving pulmonary lesions with features atypical for lymphoma should be viewed with caution
and worked up comprehensively to rule out occult second malignancies, in order to guide a prompt diagnosis and
appropriate treatment.
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Introduction
According to the World Health Organization classification
of 2008,1 mantle cell lymphoma (MCL) is classified as a
mature B-cell lymphoma, comprising about 6% of all adult
non-Hodgkin’s lymphoma (NHL) in the United States. MCL
is aggressive and usually diagnosed at an advanced stage of
the disease in middle-aged to older patients. Its incidence has
risen over recent years and is noted to be highest among
males, Caucasians, and older patients (median age 67 years
at diagnosis).2
Although an increased long-term risk for developing
secondary neoplasms, including lung cancer, has also been
described among NHL survivors,3,4 a histopathological diagnosis of 2 synchronous malignancies at the same site is
exceedingly rare. In this article, we present the case of a
middle-aged female diagnosed with MCL and primary pulmonary adenocarcinoma within the same nodule.

Case Report
A 55-year-old female presented to the emergency department for evaluation of severe lower flank pain radiating to
her lower abdomen and chest. Further review of symptoms
revealed that she also had cough, night sweats, chills, and
an unintentional weight loss of 31 pounds over 3 months.
1

Aga Khan University, Karachi, Pakistan
Medical College of Wisconsin, Milwaukee, WI, USA
3
Aurora St. Luke’s Hospital, Milwaukee, WI, USA
2

Received February 17, 2018. Revised May 28, 2018. Accepted May 31, 2018.
Corresponding Author:
Masooma Aqeel, MD, Department of Medicine, Division of Pulmonary
& Critical Care Medicine, Aga Khan University, Stadium Road, Karachi,
Sindh 74800, Pakistan.
Email: Masooma.Aqeel@aku.edu

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License
(http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further
permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

2

Journal of Investigative Medicine High Impact Case Reports

Figure 1. (a) Computed tomography scan of chest showing a 1.7 × 1.1 cm right upper lobe cavitary nodule. (b) Positron-emission
tomography scan showing extensive lymphadenopathy both above and below the diaphragm but no uptake in the right upper lobe
cavitary lesion.

Clinical examination was significant for bilateral axillary
lymphadenopathy. Subsequently, a computed tomography
(CT) scan of her chest, abdomen, and pelvis was performed
that revealed extensive bilateral lymphadenopathy (above
and below the diaphragm) as well as a new right upper lobe
(RUL) thin-walled cavitary lung lesion with spiculated
margins (Figure 1a). A positron-emission tomography (PET)CT scan showed highly metabolically active lymphadenopathy in the neck, chest, abdomen, and pelvis but minimal to
no PET avidity within the RUL cavitary lesion (Figure 1b).
Axillary lymph node sampling showed moderate-to-large
B-lymphocytes (positive for CD5, CD20, and cyclin D1),
with fluorescence in situ hybridization positive for t(11;
14), consistent with MCL. Although a bone marrow biopsy
revealed low disease burden (<10% involvement), her

lymphoma demonstrated a high proliferation rate (Ki67
proliferation index 30%), and she was diagnosed with stage
IV-B MCL.
Prior to initiation of chemotherapy, she was referred to the
pulmonary clinic for workup of the lung lesion, which was
felt to have radiographic features atypical for lymphoma.
She was an active, 30 pack-year smoker with symptoms of
stable chronic bronchitis, sinusitis, and scant hemoptysis.
Serum tuberculosis testing (TB-quantiferon) was negative.
Although no prior self-history of cancer, she had a strong
family history for cancer (lung cancer [father, paternal uncle,
and paternal grandfather], cervical cancer [mother], and premenopausal breast cancer [paternal aunt]). Chest CT was significant for severe emphysema, multiple indeterminate
pulmonary nodules, and a 1.7 × 1.1 cm, subpleural, thin-walled
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Figure 2. (a) Histopathological examination revealed an infiltrating lepidic predominant adenocarcinoma (white arrow) with coexistent
foci of lymphoid infiltrate (black arrow). (b) High-power examination revealed small, irregular, convoluted lymphocytes comprising the
lymphoid infiltrate (black arrow). Adenocarcinoma cells (white arrow) show atypical, large nuclei with prominent nucleoli (hematoxylin
and eosin). (c) Immunohistochemistry showing strong positivity for thyroid transcription factor-1.

cavitary lesion with spiculated margins in the RUL (Figure 1a).
Initial differential diagnosis included malignancy (primary/
metastatic carcinoma and less likely lymphoma), subacute or
chronic infections (such as tuberculosis and fungal infection), and vasculitis. Bronchoscopy was unremarkable, and
bronchoalveolar lavage showed 87% macrophages, 10%
neutrophils, and 2% lymphocytes, without malignant cells.
Respiratory cultures grew 1+ Aspergillus flavus. Serum antineutrophil cytoplasmic antibodies and rheumatoid arthritis
factor were negative. A short-interval (2 months) follow-up
CT imaging showed stable pulmonary nodules but a persistent
RUL cavitary lesion. A video-assisted thoracoscopic wedge
resection was performed to exclude other diagnoses prior to
initiation of chemotherapy for MCL. Pathological examination revealed a lepidic predominant, well-differentiated adenocarcinoma (pathological stage T1a), with coexistent foci of
lymphoid infiltrates within and adjacent to adenocarcinoma
(Figure 2a). The lymphoid infiltrate had histological features (convoluted irregular small nuclei; Figure 2b). By
immunohistochemistry, the adenocarcinoma component was
strongly positive with thyroid transcription factor-1, confirming pulmonary origin (Figure 2c) and discounting the

possibility of metastasis from a possible mammary carcinoma. In addition, immunohistochemical profile (positive for
B-cell markers CD20, pax5, and BCL1 [cyclin D1]; Figure 3a
and b) was consistent with MCL. Multidisciplinary consensus
was that no additional surgery, lymph node sampling, or adjuvant chemotherapy was needed. She was subsequently
observed for both adenocarcinoma and lymphoma (high proliferation rate but with low disease burden), with surveillance imaging. A year later, however, she presented with
dyspnea and a new right-sided pleural effusion (cytology
positive for adenocarcinoma, negative for epithelial growth
factor receptor/anaplastic lymphoma kinase). She received 6
cycles of carboplatin/pemetrexed/bevacizumab with good
treatment response; however, she declined further maintenance therapy due to an intolerance of side effects. A few
months later (a year ago), she presented with weight loss,
chills, and night sweats, and CT imaging showed progressive
lymphadenopathy concerning for MCL. She received ibrutinib and rituximab with good response initially; however, she
could not complete the prescribed therapy due to side effects
and was unfortunately lost to follow-up at the time of this
writing.
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Figure 3. Immunohistochemistry revealed lymphocytes showing strong and diffuse positivity for (a) generic B-cell marker CD20 and (b)
mantle cell lymphoma (MCL) marker cyclin D1.

Discussion
Our case highlights 2 important findings. First, this is a very
rare case of synchronous primary lung cancer and MCL
found within the same cavitary lung nodule. Second, this
case highlights important features of lung lesions/nodules
that would be considered “unusual or atypical” for lymphomatous involvement of the lung and raise concern for a possible secondary process in the lung.
Large population-based cancer registry reviews show
that NHL survivors are at a significantly greater risk for secondary malignancies than the normal population (all solid
tumors; observed to expected ratio = 1.37).3 This risk
remains elevated even up to 30 years after treatment for
NHL and is independent of the use of external beam radiation therapy.4 Lymphomas and leukemias tend to be among
the most common neoplasms involved even as subsequent
neoplasms, and usually arise within the first 5 years.5 Solid
tumors are more common after 5 years, with breast and lung
cancer being the most frequent.6 In a review of 77 823
patients, Tward et al demonstrated that NHL survivors have
an absolute excess cancer risk of 6.36 times (in men) and
7.10 times (in women) for a second primary lung and/or
mediastinal tumor, specifically.4
Despite these increased risks, however, a diagnosis of a
synchronous second malignancy with a coexistent lymphoproliferative disorder is still quite rare. Synchronous multiple
primary cancers are defined as 2 or more primary tumors
occurring within 6 months of each other.7,8 In reviewing the
medical literature, it appears that an association between
NHL and breast cancer is well recognized. Wiernik et al, in a
large series of 87 cases, established that in women with both
breast cancer and NHL, lymphoma is significantly more likely
to be diagnosed after or concurrently with breast cancer. The 2
malignancies could be seen in separate organs, or as “collision
tumors,” with coexistence in anatomic proximity to each

other.9 Experimental evidence also appears to suggest that
breast cancer and lymphoma of the breast may share some
common biologic characteristics.10 However, we found only
a handful of case reports that document synchronous NHL
and primary lung cancer.11-13 Within NHL, MCL appears to
be more commonly associated with secondary genitourinary
malignancies rather than lung cancer.14 Where authors report
synchronous MCL and primary lung cancer, it is either at
separate sites15 or in the form of metastases to the same
regional lymph node.16 We found only 2 reports describing
synchronous involvement of same thoracic site (ie, pleura)
by both MCL and primary lung cancer17,18 (summarized in
Table 1). Our case adds itself to a rare but growing list of
reports of synchronous MCL and primary lung cancer, and is
also the first, to our knowledge, to report synchronous MCL
and primary lung cancer within the same cavitary lung nodule (“collision histology”).
The biological mechanisms behind the pathogenesis of
such synchronous multiple primary malignancies are still
largely unknown. Authors have proposed certain mechanisms
such as the possible spread of cancerous cells from a single
clone to multiple sites,19 genetic defects involving mismatch
repair systems,20 a positive family history of malignancy,8
and/or a complex interplay of genetics, impaired immunity,
viremia (ie, Epstein-Barr virus, etc), and carcinogenic risk
factors (such as smoking) that ultimately all contribute to the
development of synchronous multiple primary cancers.5 It is
plausible that both complex genetics and history of smoking
placed our patient at risk for these 2 tumors.
Second, this case highlights some important diagnostic
and radiological considerations. It is conceivable that the
detection of a second pulmonary malignancy was simply an
incidental finding in our patient (a smoker) and that a lymphoma staging workup essentially replaced what could
have been routine age-appropriate lung cancer screening
otherwise (our center sees about 2 to 3 such cases annually
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Table 1. Case Reports Citing Synchronous Occurrence of Non-Hodgkin’s Lymphoma and Primary Lung Cancer.
Title

Authors

Year

Site

Case Description

Coexistence of non-Hodgkin’s
lymphoma and non–small-cell
lung carcinoma: diagnosis and
treatment

Rothenburger
et al11

2001

Different sites;
lung mass and
lymph nodes

Synchronous pulmonary
adenocarcinoma and extranodal
marginal zone/low-grade B-cell
lymphoma of the MALT type
Mantle cell lymphoma in lymph
nodes with metastatic small cell
carcinoma of lung: a diagnostic
and treatment dilemma
A rare tumoral combination,
synchronous lung
adenocarcinoma and mantle cell
lymphoma of the pleura
Synchronous pulmonary
squamous cell carcinoma and
mantle cell lymphoma of the
lymph node

Chanel et al12

2001

Same site
(pulmonary
mass)

Kampalath
et al16

2004

Same site
(lymph nodes)

A 67-year-old NHL survivor developed new diffuse
lymphadenopathy and a pulmonary mass. Inguinal lymph
node biopsy revealed relapsed NHL. Due to lack of
treatment response seen in the pulmonary mass, a
complex lobectomy was performed and revealed a
secondary non–small-cell lung cancer.
An interesting case of a 74-year-old male with a
nonresolving pulmonary mass that was surgically
removed to reveal synchronous adenocarcinoma and
extranodal low-grade B-cell lymphoma of the MALT type.
A 58-year-old female with metastatic small cell lung cancer
with synchronous mantle cell lymphoma.

Hatzibougias
et al18

2008

Same site
(pleura)

Sun et al15

2011

Different sites;
lung mass and
lymph nodes

Synchronous BALT lymphoma
and squamous cell carcinoma
of the lung: coincidence or
linkage?

Oikonomou
et al13

2013

Different sites;
2 nodules
in separate
lobes

Synchronous pulmonary
malignancies: atypical
presentation of mantle cell
lymphoma masking a lung
malignancy

Masha et al17

2015

Same site
(pleura)

A 73-year-old male who underwent a bullectomy for
persistent pneumothorax was incidentally diagnosed
with synchronous pulmonary adenocarcinoma and MCL
of the pleura.
A 57-year-old male presenting with a right lower
lobe pulmonary mass and cervical and mediastinal
lymphadenopathy. The lung mass was biopsied to show
squamous cell lung cancer and the lymphadenopathy
revealed MCL.
A 72-year-old male presents with 2 large masses (one in
the right middle lobe and another in left lower lobe).
Biopsy of the left lobe revealed a BALT lymphoma.
When the right mass did not respond to lymphoma
therapy, a second biopsy was done and revealed
concomitant squamous cell lung cancer.
A 70-year-old male presented with a large right pleural
effusion. Pleural fluid analysis clonal populations
consistent with mantle cell lymphoma. He underwent
treatment for lymphoma with no improvement. A
CT-guided biopsy then revealed tissue consistent with
undifferentiated carcinoma, favoring lung primary.

Abbreviations: NHL, non-Hodgkin’s lymphoma; MALT, mucosa-associated lymphoid tissue; MCL, mantle cell lymphoma; BALT, bronchus-associated
lymphoid tissue; CT, computed tomography.

[personal communication]). However, this case emphasizes
that it is also important to be cognizant of the “usual” or
“typical” patterns of lung involvement with lymphoma.
Extranodal thoracic involvement is not uncommon with
NHL and may represent either primary pulmonary lymphoma or secondary spread. Common radiographic patterns
of lymphomatous pulmonary involvement include diffuse
interstitial thickening, mass-like consolidation with homogenous attenuation, air-bronchograms and preserved vascular
markings, perilymphatic nodularity, and PET avidity in the
lung similar to other known sites involved with NHL.21 This
lesion was atypical given its isolated, peripheral, “cavitary”
nature and without any significant PET avidity in comparison with surrounding lymphadenopathy (Figure 1b). Instead,
an extensive smoking history coupled with radiographic
findings of a single cavitary lesion with spiculated margins,
measuring more than 10 mm in size, made her odds of

having a potential secondary process such as a lung malignancy much more likely.
It is also important to note an “unresolving” nature of certain pulmonary lesions/nodules. In several prior published
reports, we observe that an initial diagnosis is often reached
via a biopsy of a certain site. However, it is the “unresolving”
nature or “lack of a complete response” to appropriate therapy that often prompts physicians to search for an alternate
or synchronous diagnosis.11-13,17
In summary, we describe here a very unusual case of
MCL and primary pulmonary adenocarcinoma presenting
synchronously within one cavitary lung lesion. Synchronous
malignancies such as these are exceedingly rare and crucial
to identify promptly as treatment can be markedly different.
This case highlights the importance of a high index of clinical suspicion of lesions that do not resolve on short-term
follow-up (either spontaneously or with treatment) and a
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keen radiologic awareness of the features that would be
unusual for lymphomatous involvement of the lung.

6.
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